(sevelamer carbonate) in the United States, Synvisc-ONE(TM) (hylan
G-F 20) and Cholestagel(R) (colesevelam hydrochloride) in the
European Union, and Elaprase(R) (idursulfase) in Japan-and secured
expanded U.S. labeling for Campath(R) (alemtuzumab) and Thyrogen(R)
(thyrotropin alfa for injection).
-- Reported highly encouraging clinical trial results for two key late
stage product candidates: Mozobil(TM) (plerixafor) for stem-cell
transplantation and alemtuzumab for multiple sclerosis.
Fourth-Quarter 2007 Highlights
-- Revenue increased 21 percent in the fourth quarter to $1.04 billion, up
from $854.2 million in the prior fourth quarter.
-- GAAP net income increased to $78.9 million, or $0.29 per diluted share,
compared with an acquisition-related net loss of $268.2 million, or
$1.02 per diluted share, in the prior fourth quarter.
-- Non-GAAP net income increased 19 percent to $249.2 million, compared
with $209.0 million in the previous fourth quarter.
-- Non-GAAP earnings rose 18 percent to $0.91 per diluted share from
$0.77. The increased operating expenses and decreased interest income
associated with Genzyme's fourth-quarter acquisition of Bioenvision
reduced earnings by $0.01 per diluted share. The company had noted
previously that the impact of this transaction would be reflected in
its fourth-quarter results.
-- Individual product sales for the fourth quarter and the year, along
with expectations for the longer-term growth of Genzyme's business
segments, were detailed in a January 8, 2008, press release coinciding
with the company's presentation at the JPMorgan Healthcare Conference.
"We delivered outstanding financial results last year while continuing
to build the company to meet our goa
|SOURCE Genzyme Corporation|
Copyright©2008 PR Newswire.
All rights reserved